Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Reporting Period: Event-based report for March 19, 2026.
The Company, incorporated in Alberta, Canada, operates in the biotechnology sector. This filing reports the acceptance of two clinical study abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific corporate event (Item 8.01) and does not provide quantitative financial metrics.
Material Changes
No material financial changes versus prior periods are reported in this document. The material event is the acceptance of abstracts for two clinical studies:
- GOBLET Study: Data from Cohort 1 in metastatic pancreatic ductal adenocarcinoma patients.
- AWARE-1 Study: Data in breast cancer patients.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the abstract acceptance. No specific financial guidance or forward-looking projections regarding revenue or earnings are included in this filing text.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard incorporation of the press release. As with clinical data presentations, the ultimate interpretation of the data and regulatory outcomes remain subject to future developments.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data results and statistical significance.
- Confirm the dates and location of the AACR Annual Meeting presentation.
- Review the Company's Registration Statement on Form F-3 (File No. 333-289819) as this 8-K is incorporated by reference into it.
- Check subsequent filings for any updates on the GOBLET and AWARE-1 study outcomes.